SAN DIEGO, September 28, 2015 /PRNewswire/ --
Dr. Christine Ichim will present at Stem Cell Meeting on the Mesa
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today that Dr. Christine Ichim, Director of Molecular Therapeutics at Regen, was selected by the organizers of Stem Cell Meeting on the Mesa to speak at the conference regarding ongoing leukemia research being conducted by the company. The Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior executives and top decision makers in the regenerative medicine industry with the scientific community to advance cutting-edge research into cures.
As part of the speaker line-up during the three-day conference, Dr. Ichim will deliver a presentation on how silencing of a novel leukemia target using DiffronC siRNA technology induces terminal differentiation of murine hematopoietic stem and progenitor cells. The silencing of the expression of this orphan nuclear receptor suggests that this is a logical therapeutic target for differentiation therapy using gene silencing technology.
Along with Dr. Ichim, the research team on this Regen BioPharma, Inc. project included research scientists at the University of Toronto.
Stem Cell Meeting on the Mesa begins on October 7. Dr. Ichim will present on October 9 at The Salk Institute during the Scientific Symposium portion of the conference.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
SOURCE Regen BioPharma Inc.